



## NEWS RELEASE

### **For Further Information Contact:**

Roy Wolvin  
Nymox Pharmaceutical Corporation  
1-800-93NYMOX  
www.nymox.com

### **For Immediate Release:**

## **NicAlert™ Study in Children to be Presented at American Thoracic Society Conference in San Francisco**

HASBROUCK HEIGHTS, NJ (May 17, 2007) Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that the results of an important pediatric second-hand smoke study of the Company's NicAlert™ product will be the subject of a podium presentation by Professor Anne Turner Henson of the University of Alabama at the International Conference of the American Thoracic Society in San Francisco on May 20, 2007. The study involved 100 pre-school children who were investigated for second-hand smoke exposure, smokers in the family, and other health issues.

NicAlert™ employs the Company's proprietary technology to measure levels of cotinine, a metabolite of nicotine widely used to determine tobacco product use and second-hand smoke exposure. The product requires no instruments for its use and provides an on-site visual read-out of the level of tobacco use or exposure within minutes.

The urine-based version of NicAlert™ received clearance from the U.S. Food and Drug Administration to measure tobacco use and exposure and achieved certification for sale in the European Union with the CE Mark. A saliva-based version of NicAlert™ has achieved certification with the CE Mark, permitting its sale in the European Union. NicAlert™ can be used with both urine and saliva samples. TobacAlert™ which employs the same technology is available as an over-the counter product in the U.S. for detecting second-hand smoke exposure.

Researchers at the Centers for Disease Control and Prevention (CDC) authored a study in the peer-review literature using NicAlert™ (*Journal of Analytical Toxicology* 2005; 29: 814-818) and found that NicAlert™ measurements correlated well with the far more complex laboratory testing (liquid chromatography-mass spectrometry) used in the CDC laboratory. Other independent peer-reviewed studies have also found the technology employed in NicAlert™ to be accurate, rapid and cost-effective (*Cancer Epidemiology, Biomarkers & Prevention* 2002; 11: 1123-1125; *Nicotine & Tobacco Research* 2002; 4: 305-9).

The International Conference of the American Thoracic Society is one of the largest gatherings of Pulmonary and Critical Care clinicians and researchers in the world and covers a broad range of topics relating to lung disease and health advocacy and education, including asthma, the environment, chronic obstructive pulmonary disease, tobacco control, lung cancer, and pediatric lung disease. Last year's conference was attended by over 14,000 people from 90 countries.

Second-hand smoke poses a serious and pervasive health risk to children and adults according to the 2006 U.S. Surgeon General report, *The Health Consequences of Involuntary Exposure to Tobacco Smoke*. The report highlighted how vulnerable children in particular are to second-hand smoke. Children exposed to secondhand smoke are at an increased risk for sudden infant death syndrome (SIDS), acute respiratory infections, ear problems, and more severe asthma. The report also links second-hand smoke to coronary heart disease and lung cancer in adults and notes that even a brief exposure to second-hand smoke has immediate adverse effects on a person's cardiovascular system. The California Environmental Protection Agency has estimated that secondhand smoke exposure causes approximately 3,400 lung cancer deaths and 22,700–69,600 heart disease deaths annually among adult nonsmokers in the United States.

More information about Nymox is available at [www.nymox.com](http://www.nymox.com), email: [info@nymox.com](mailto:info@nymox.com), or 800-936-9669.

*This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.*